These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30502634)

  • 21. In silico identification and biological evaluation of novel selective serum/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold.
    Ortuso F; Amato R; Artese A; D'antona L; Costa G; Talarico C; Gigliotti F; Bianco C; Trapasso F; Schenone S; Musumeci F; Botta L; Perrotti N; Alcaro S
    J Chem Inf Model; 2014 Jul; 54(7):1828-32. PubMed ID: 24896223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, Cytotoxicity, Antimicrobial and Docking Simulation of Novel Pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[3,4-c] pyrimidine Derivatives.
    Hassaneen HM; Saleh FM; Abdallah TA; Mohamed MF; Mohamed YS; Awad EM; Abdelhamid IA
    Mini Rev Med Chem; 2019; 19(8):657-670. PubMed ID: 30332953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, antibacterial activity and cytotoxicity of new fused pyrazolo[1,5-a]pyrimidine and pyrazolo[5,1-c][1,2,4]triazine derivatives from new 5-aminopyrazoles.
    Al-Adiwish WM; Tahir MI; Siti-Noor-Adnalizawati A; Hashim SF; Ibrahim N; Yaacob WA
    Eur J Med Chem; 2013 Jun; 64():464-76. PubMed ID: 23669354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.
    Da Settimo F; Primofiore G; La Motta C; Taliani S; Simorini F; Marini AM; Mugnaini L; Lavecchia A; Novellino E; Tuscano D; Martini C
    J Med Chem; 2005 Aug; 48(16):5162-74. PubMed ID: 16078836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation.
    Vekariya MK; Vekariya RH; Brahmkshatriya PS; Shah NK
    Chem Biol Drug Des; 2018 Sep; 92(3):1683-1691. PubMed ID: 29767460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonists of 5-HT₆ receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines-Synthesis and 'structure-activity' relationship.
    Ivachtchenko AV; Golovina ES; Kadieva MG; Kysil VM; Mitkin OD; Vorobiev AA; Okun I
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4273-80. PubMed ID: 22664127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques.
    Amin SA; Bhargava S; Adhikari N; Gayen S; Jha T
    J Biomol Struct Dyn; 2018 Feb; 36(3):590-608. PubMed ID: 28132591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New advances in synthesis and clinical aspects of pyrazolo[3,4-d]pyrimidine scaffolds.
    Abdellatif KRA; Bakr RB
    Bioorg Chem; 2018 Aug; 78():341-357. PubMed ID: 29627655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors.
    Cai J; Bennett DJ; Rankovic Z; Dempster M; Fradera X; Gillespie J; Cumming I; Finlay W; Baugh M; Boucharens S; Bruin J; Cameron KS; Hamilton W; Kerr J; Kinghorn E; McGarry G; Robinson J; Scullion P; Uitdehaag JC; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4447-50. PubMed ID: 20594841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening of curcumin-derived isoxazole, pyrazoles, and pyrimidines for their anti-inflammatory, antinociceptive, and cyclooxygenase-2 inhibition.
    Ahmed M; Qadir MA; Hameed A; Imran M; Muddassar M
    Chem Biol Drug Des; 2018 Jan; 91(1):338-343. PubMed ID: 28741789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of pyrazolo[4,3-d]pyrimidine analogues.
    Yuan L; Song C; Li C; Li Y; Dong L; Yin S
    Eur J Med Chem; 2013 Sep; 67():152-7. PubMed ID: 23851116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient construction of pyrazolo[1,5-a]pyrimidine scaffold and its exploration as a new heterocyclic fluorescent platform.
    Wu YC; Li HJ; Liu L; Wang D; Yang HZ; Chen YJ
    J Fluoresc; 2008 Mar; 18(2):357-63. PubMed ID: 18008150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.
    Wustrow DJ; Capiris T; Rubin R; Knobelsdorf JA; Akunne H; Davis MD; MacKenzie R; Pugsley TA; Zoski KT; Heffner TG; Wise LD
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2067-70. PubMed ID: 9873487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.
    Fang Z; Wang TQ; Li H; Zhang G; Wu XA; Yang L; Peng YL; Zou J; Li LL; Xiang R; Yang SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3201-3204. PubMed ID: 28539219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system.
    Azam MA; Dharanya L; Mehta CC; Sachdeva S
    Acta Pharm; 2013 Mar; 63(1):19-30. PubMed ID: 23482310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.